Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2019	Jun. 01, 2019	Sep. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		130,227,053
Entity Public Float			$ 131,933,864

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 36,477	$ 43,726
Accounts receivable	503	883
Grant receivable	55	145
Inventory, net	490	842
Prepaid expenses and other current assets	1,049	1,164
Total current assets	38,574	46,760
Fixed assets, net	1,832	2,788
Restricted cash	79	127
Other assets, net	138	152
Total assets	40,623	49,827
Current Liabilities
Accounts payable	628	464
Accrued expenses	2,549	3,341
Deferred revenue	525	668
Deferred rent	35	185
Total current liabilities	3,737	4,658
Deferred revenue, net of current portion	0	19
Deferred rent, net of current portion	588	564
Total liabilities	4,325	5,241
Commitments and Contingencies	0	0
Stockholders' Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 124,015,429 and 111,032,957 shares issued and outstanding at March 31, 2019 and March 31, 2018, respectively	124	111
Additional paid-in capital	296,929	278,595
Accumulated deficit	(260,755)	(234,120)
Total stockholders' equity	36,298	44,586
Total Liabilities and Stockholders' Equity	$ 40,623	$ 49,827

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Mar. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	124,015,429	111,032,957
Common stock, shares outstanding	124,015,429	111,032,957

Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues
Total Revenues	$ 3,091	$ 4,603
Cost of revenues	482	1,030
Research and development expenses	14,752	17,956
Selling, general, and administrative expense	15,131	20,888
Total costs and expenses	30,365	39,874
Loss from Operations	(27,274)	(35,271)
Other Income (Expense)
Gain (loss) on fixed asset disposals	(63)	4
Interest income	705	478
Other income (expense)	0	(12)
Total Other Income (Expense)	642	470
Income Tax Expense	(3)	(2)
Net Loss	$ (26,635)	$ (34,803)
Net loss per common share—basic and diluted	$ (0.23)	$ (0.32)
Weighted average shares used in computing net loss per common share—basic and diluted	115,379,902	107,243,974
Comprehensive Loss:
Net Loss	$ (26,635)	$ (34,803)
Currency Translation Adjustment	0	11
Comprehensive Loss	(26,635)	(34,792)
Products and Services [Member]
Revenues
Total Revenues	2,333	3,627
Collaborations and Licenses [Member]
Revenues
Total Revenues	171	422
Grants [Member]
Revenues
Total Revenues	$ 587	$ 554

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Mar. 31, 2017	$ 62,362	$ 104	$ 261,586	$ (199,317)	$ (11)
Beginning balance, Shares at Mar. 31, 2017		104,551,000
Stock option exercises	$ 826	$ 1	825	0	0
Stock option exercises, Shares	500,000	500,000
Issuance of common stock under employee and director stock option, RSU and purchase plans	$ 114	$ 1	113	0	0
Issuance of common stock under employee and director stock option, RSU and purchase plans, Shares		675,000
Stock-based compensation expense	6,903	$ 0	6,903	0	0
Issuance of common stock from public offering, net	9,173	$ 5	9,168	0	0
Issuance of common stock from public offering, Shares		5,307,000
Net loss	(34,803)	$ 0	0	(34,803)	0
Currency Translation Adjustment	11	0	0	0	11
Ending balance at Mar. 31, 2018	44,586	$ 111	278,595	(234,120)	0
Ending balance, Shares at Mar. 31, 2018		111,033,000
Stock option exercises	$ 50	$ 1	49	0	0
Stock option exercises, Shares	622,192	622,000
Issuance of common stock under employee and director stock option, RSU and purchase plans	$ (139)	$ 1	(140)	0	0
Issuance of common stock under employee and director stock option, RSU and purchase plans, Shares		728,000
Stock-based compensation expense	5,193	$ 0	5,193	0	0
Issuance of common stock from public offering, net	13,243	$ 11	13,232	0	0
Issuance of common stock from public offering, Shares		11,632,000
Net loss	(26,635)	$ 0	0	(26,635)	0
Currency Translation Adjustment	0
Ending balance at Mar. 31, 2019	$ 36,298	$ 124	$ 296,929	$ (260,755)	$ 0
Ending balance, Shares at Mar. 31, 2019		124,015,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities
Net loss	$ (26,635)	$ (34,803)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss on disposal of fixed assets	63	(4)
Depreciation and amortization	980	1,267
Stock-based compensation	5,193	6,903
Donation of fixed assets	0	25
Increase (decrease) in cash resulting from changes in:
Accounts receivable	380	(236)
Grants receivable	90	(145)
Inventory	352	(292)
Prepaid expenses and other assets	118	5
Accounts payable	164	(707)
Accrued expenses	(792)	(760)
Deferred revenue	(162)	(157)
Deferred rent	(126)	47
Net cash used in operating activities	(20,375)	(28,857)
Cash Flows From Investing Activities
Purchases of fixed assets	(79)	(226)
Proceeds from disposals of fixed assets	3	4
Purchases of intangible assets	0	(70)
Net cash used in investing activities	(76)	(292)
Cash Flows From Financing Activities
Proceeds from issuance of common stock	13,327	9,381
Employee taxes paid related to net share settlement of equity awards	(223)	(94)
Proceeds from exercise of stock options	50	826
Net cash provided by financing activities	13,154	10,113
Effect of currency exchange rate changes on cash and cash equivalents	0	11
Net Decrease in Cash and Cash Equivalents	(7,297)	(19,025)
Cash, cash equivalents, and restricted cash at beginning of period	43,853	62,878
Cash, cash equivalents, and restricted cash at end of period	36,556	43,853
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	36,477	43,726
Restricted cash	79	127
Cash, cash equivalents, and restricted cash at end of period	36,556	43,853
Supplemental Disclosure of Cash Flow Information:
Income Taxes	$ 3	$ 2

Description of Business and Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Description of Business and Summary of Significant Accounting Policies

1. Description of Business and Summary of Significant Accounting Policies

Nature of operations and basis of presentation

Organovo Holdings, Inc. (“Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company”) is a biotechnology company pioneering the development of bioprinted human tissues that emulate human biology and disease. Initially, we are developing our in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. Our objective is to serve as a ‘bridge-to-transplant’ for these patients, with an ultimate goal of delaying or reducing the overall need for transplant. The Company’s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. We are also utilizing our foundational ability to isolate highly specialized human cells to build robust, functional human tissues by creating a range of novel preclinical in vitro disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions. Our clients can access these diseased tissue platforms through collaborative, revenue-generating agreements.

Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo UK Ltd in March 2018, the U.K. operations were combined with Organovo, Inc.’s operations.

The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology, failing to achieve regulatory approvals for its therapeutic candidates, and failing to achieve the market acceptance necessary to generate sufficient revenues to achieve and sustain profitability.

Reclassification of prior year presentation

As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position.

Nasdaq listing

On August 8, 2016, the Company moved its stock exchange listing to the Nasdaq Global Market, under the “ONVO” ticker symbol. From July 11, 2013 through August 5, 2016, the Company listed its shares on the NYSE MKT. Prior to July 11, 2013, the Company’s shares were quoted on the OTC QX.

Liquidity

As of March 31, 2019, the Company had cash and cash equivalents of approximately $36.5 million and restricted cash of less than $0.1 million. The restricted cash was pledged as collateral for two letters of credit the Company is required to maintain as security deposits under the terms of the leases of its facilities. The Company had an accumulated deficit of approximately $260.8 million. The Company also had negative cash flows from operations of approximately $20.4 million during the year ended March 31, 2019.

Through March 31, 2019, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, grants, and licenses. During the year ended March 31, 2019, the Company issued 11,631,803 shares of its common stock through its ATM facility and received net proceeds of approximately $13.2 million.

Based on its current operating plan and available cash resources, the Company believes it has sufficient resources to fund its business for at least the next twelve months.

The Company will need additional capital to further fund the development of its proprietary platform to produce and study living tissues focusing on critical unmet medical needs in the liver disease space. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative agreements, grants and license payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders.

Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.

Financial instruments

For certain of the Company’s financial instruments, including cash and cash equivalents, inventory, prepaid expenses and other assets, accounts payable, accrued expenses, deferred revenue, and capital lease obligations, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.

Cash and cash equivalents

The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.

Foreign Currency

The functional currency of our U.K. operations was the pound sterling. Accordingly, all assets and liabilities of this subsidiary were translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components were translated to US dollars at the exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets.

Foreign currency transaction gains and losses, which are primarily the result of remeasuring United States dollar-denominated receivables and payables, are recorded in our Consolidated Statements of Operations and Other Comprehensive Loss. For the years ended March 31, 2019 and 2018, we recognized foreign currency translation losses of approximately $0 and $1,000, respectively.

As of March 31, 2019 and 2018, we realized $0 and $11,000 of cumulative foreign currency translation losses as Other Expense on the Consolidated Statement of Operations and Other Comprehensive Loss for the years ending March 31, 2019 and 2018, respectively. No further foreign currency translation losses will be recorded as the U.K. operations have been combined with Organovo, Inc.’s operations as of March 31, 2018.

Restricted cash

As of March 31, 2019 and 2018, the Company had approximately $79,000 and $127,000 of restricted cash, respectively, deposited with a financial institution. The entire amount is held in certificates of deposit to support a letter of credit agreement related to the Company’s facility lease.

Inventory

Inventories are stated at the lower of the cost or net realizable value (first-in, first-out). Inventory at March 31, 2019 consists of approximately $361,000 in raw materials, approximately $0 in work-in-process inventory, and approximately $129,000 in finished goods net of reserve. Inventory at March 31, 2018 consisted of approximately $578,000 in raw materials, approximately $26,000 in work-in progress inventory, and approximately $238,000 in finished goods net of reserve.

Fixed assets and depreciation

Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the remaining lease term. The estimated useful lives of the fixed assets range between one and seven years.

Impairment of long-lived assets

In accordance with authoritative guidance, the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred as of March 31, 2019.

Research and development

Research and development expenses, including direct and allocated expenses, consist of independent research and development costs, as well as costs associated with sponsored research and development. Research and development costs are expensed as incurred.

Income taxes

Deferred income taxes are recognized for the tax consequences in future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.

Revenue recognition

The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations.

Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of March 31, 2019 and 2018, the Company had approximately $525,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the twelve months ended March 31, 2019 the Company recognized revenue on approximately $178,000 that had been recorded as deferred revenue at March 31, 2018.

Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Service revenues

The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606.

For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration.

Product sales, net

The Company’s product-based business, Samsara Sciences, Inc., produces cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted.

The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly.

Collaborative research, development, and licenses

The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”).

The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.

The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract.

For the year ended March 31, 2019, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements.

Grant revenues

In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does not meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency.

Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606.

Revenue recognized under this grant was approximately $587,000 and $554,000 during the years ended March 31, 2019 and 2018, respectively.

Cost of revenue

The Company reported $0.5 million and $1.0 million in cost of revenue for the years ended March 31, 2019 and 2018, respectively. Cost of revenues consists of our costs related to manufacturing and delivering our product and service revenue.

Stock-based compensation

The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board’s ASC Topic 718, Compensation — Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).

The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity-based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.

Comprehensive income (loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended March 31, 2019 and 2018, the comprehensive loss was materially equal to the net loss and consisted of net loss and foreign currency translation. As of March 31, 2019, unrealized foreign currency translation previously recorded in other comprehensive loss was realized and recorded to other expense.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the years ended March 31, 2019 and 2018 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share were approximately 14.4 million and 12.6 million for the years ended March 31, 2019 and 2018, respectively.

Fixed Assets

12 Months Ended

Mar. 31, 2019

Property Plant And Equipment [Abstract]

Fixed Assets

2. Fixed Assets

Fixed assets consisted of the following (in thousands):

	March 31, 2019			March 31, 2018
Construction in Progress	$	47		$	—
Laboratory equipment	$	3,690		$	3,695
Leasehold improvements		1,809			2,177
Computer software and equipment		645			656
Furniture and fixtures		213			319
Vehicles		9			9
Fixed Assets, gross		6,413			6,856
Less accumulated depreciation		(4,581	)		(4,068	)
Fixed Assets, net	$	1,832		$	2,788

Depreciation expense for the years ended March 31, 2019 and 2018 was approximately $969,000 and $1,253,000, respectively.

Accrued Expenses

12 Months Ended

Mar. 31, 2019

Payables And Accruals [Abstract]

Accrued Expenses

3. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	March 31, 2019		March 31, 2018
Accrued compensation	$	2,160	$	2,735
Accrued legal and professional fees		152		99
Other accrued expenses		237		507
	$	2,549	$	3,341

Collaborative Research, Development, and License Agreements

12 Months Ended

Mar. 31, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Research, Development, and License Agreements

4. Collaborative Research, Development, and License Agreements

In April 2015, the Company entered into a research collaboration agreement with a third party to develop custom tissue models for fixed fees. Based on the proportional performance achieved under this agreement for the years ended March 31, 2019 and 2018, the Company has recorded approximately $0 and $150,000, respectively, in collaboration revenue. The Company has completed its obligations under this agreement as of March 31, 2018.

In June 2016, the Company entered into a collaborative nonexclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter^® at the university for the purpose of developing bioprinted tissues for skeletal disease research. The Company received an up-front payment in June 2016, which has initially been recorded as deferred revenue. Revenues of $0 and $65,000 were recognized under this agreement during the years ended March 31, 2019 and 2018, respectively. The Company does not anticipate recording any further revenue under this agreement.

In December 2016, the Company signed another collaborative nonexclusive research affiliation with a university medical school and a non-profit medical charity, under which the Company received a one-time grant from the charity towards the placement of a NovoGen Bioprinter^® at the university for the purpose of developing an architecturally correct kidney for potential therapeutic applications. The Company received up-front payments in January and March of 2017, which has been recorded as deferred revenue. Revenue of $39,000 has been recorded under this agreement during each of the years ended March 31, 2019 and 2018.

In April 2017, the Company signed a collaborative non-exclusive research affiliation with a university, under which the Company received a one-time nonrefundable payment toward the placement of a NovoGen Bioprinter^® at the university for the purpose of specific research projects mutually agreed upon by the university and the Company in the field of volumetric muscle loss. The Company received an up-front payment in May 2017, which was recorded as deferred revenue. Revenue of approximately $57,000 and $43,000 has been recorded during the year ended March 31, 2019 and 2018, respectively, beginning subsequent to the installation of the printer in July of 2017. In addition, during April 2017, the Company signed a non-exclusive patent license agreement with the university including an annual fee of $75,000 for each of two years for the license to Company patents for research use limited to the field of volumetric muscle loss. The Company received the first annual payment of $75,000 in April 2017, which was initially recorded as deferred revenue. The Company received the second annual payment of $75,000 in May 2018. Revenue of $75,000 has been recorded under this agreement during each of the years ended March 31, 2019 and 2018.

In September 2017, the Company entered into an agreement with a company, under which the Company received a one-time non-refundable payment of $50,000 for limited use of a Company patent in reference to four bioprinters developed and placed at research and academic facilities. The Company has recorded $0 and $50,000 in revenue during the year ended March 31, 2019 and 2018, respectively.

Stockholders' Equity

12 Months Ended

Mar. 31, 2019

Equity [Abstract]

Stockholders' Equity

5. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based awards include stock options and restricted stock units under the 2012 Equity Incentive Plan, as amended (“2012 Plan”) and Inducement Awards, performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and rights to purchase stock under the 2016 Employee Stock Purchase Plan (“ESPP”). The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense.

Stock-based compensation expense for all stock awards consists of the following (in thousands):

	Year Ended March 31, 2019		Year Ended March 31, 2018
Research and development	$	911	$	1,174
General and administrative	$	4,282	$	5,729
Total	$	5,193	$	6,903

The total unrecognized compensation cost related to unvested stock option grants as of March 31, 2019 was approximately $7,439,000 and the weighted average period over which these grants are expected to vest is 2.74 years.

The total unrecognized stock-based compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of March 31, 2019 was approximately $3,234,000, which will be recognized over a weighted average period of 2.49 years.

The total unrecognized stock-based compensation cost related to unvested performance-based restricted stock units as of March 31, 2019 was approximately $136,000, which will be recognized over a weighted average period of 4.07 years.

The total unrecognized stock-based compensation cost related to unvested employee stock purchase plan (“ESPP”) shares as of March 31, 2019 was approximately $10,000, which will be recognized over a period of 5 months.

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Year Ended March 31, 2019			Year Ended March 31, 2018
Dividend yield		—			—
Volatility		72.99	%		76.86	%
Risk-free interest rate		2.75	%		1.81	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	0.84		$	1.73

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Considering the expected life of these options, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available is more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested.

The fair value of each restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the Company’s ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:

	Year Ended March 31, 2019		Year Ended March 31, 2018
Dividend yield		—		—
Volatility	43.7 - 80.2%		43.0% - 74.7%
Risk-free interest rate	1.85 - 2.52%		0.79% - 1.85%
Expected term	6 months		6 months
Grant date fair value	$ 0.29 - $0.45		$ 0.30 - $1.04

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. For the first full year of ESPP offering periods, beginning September 1, 2016, the Company determined that a blend of historical volatility and implied volatility of comparable companies whose share prices are publicly available was more reflective of market conditions and a better indicator of expected volatility than using purely Company-specific historical volatility. As of September 1, 2017 and the beginning of the second year of ESPP offering periods, the Company is using the Company-specific historical volatility rate as the 6-month historical volatility is now a better indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period.

Preferred stock

The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no present plans to issue shares of preferred stock.

Common stock

In May of 2008, the Board of Directors of the Company approved the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan authorized the issuance of up to 1,521,584 common shares for awards of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock award units, and stock appreciation rights. The 2008 Plan terminated on July 1, 2018. As of March 31, 2019, 896,256 shares under the 2008 Plan have been issued.

In January 2012, the Board of Directors of the Company approved the 2012 Plan. The 2012 Plan authorized the issuance of up to 6,553,986 shares of common stock for awards of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance units, performance shares, and other stock or cash awards. The Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2013 to increase the number of shares of common stock that may be issued under the 2012 Plan by 5,000,000 shares. In August 2015, the Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan in August 2015 to further increase the number of shares of common stock that may be issued under the 2012 Plan by 6,000,000 shares. In July 2018, the Board of Directors and stockholders of the Company approved an amendment to the 2012 Plan to further increase the number of shares of common stock that may be issued under the 2012 Plan by 11,000,000 shares, bringing the aggregate shares issuable under the 2012 Plan to 28,553,986. The 2012 Plan as amended and restated became effective on July 26, 2018 and terminates ten years after such date. As of March 31, 2019, 13,464,720 shares remain available for issuance under the 2012 Plan.

On April 24, 2017 the Company filed a Registration Statement on Form S-8 with the SEC authorizing the issuance of 2,297,034 shares of the Company’s Common Stock, pursuant to the terms of an Inducement Award Stock Option Agreement and an Inducement Award Performance-Based Restricted Stock Unit Agreement (collectively, the “Inducement Award Agreements”).

On August 14, 2018 the Company filed a Registration Statement on Form S-8 with the SEC authorizing the issuance of 1,135,408 shares of the Company’s Common Stock, pursuant to the terms of an Inducement Award Stock Option Agreement and an Inducement Award Restricted Stock Unit Agreement (collectively, the “Inducement Award Agreements”).

The Company filed a shelf registration statement on Form S-3 (File No. 333-189995), or the 2013 Shelf, with the SEC on July 17, 2013 authorizing the offer and sale in one or more offerings of up to $100,000,000 in aggregate of common stock, preferred stock, debt securities, or warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. This 2013 Shelf was declared effective by the SEC on July 26, 2013.

A shelf registration statement on Form S-3 (File No. 333-202382), or the 2015 shelf, was filed with the SEC on February 27, 2015 authorizing the offer and sale in one or more offerings of up to $190,000,000 in aggregate of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities. The 2015 shelf was declared effective by the SEC on March 17, 2015.

In December 2014, the Company entered into an equity offering sales agreement (“2014 Sales Agreement”) with an investment banking firm. Under the terms of the sales agreement, the Company was eligible to offer and sell shares of its common stock, from time to time, through the investment bank in at-the-market offerings, as defined by the SEC, and pursuant to the Company’s 2013 Shelf. During the year ended March 31, 2018, the Company issued 5,307,105 shares of common stock in at-the-market offerings under the sales agreement with net proceeds of $9.2 million. The 2014 Sales Agreement expired on March 17, 2018. Prior to its expiration, the Company sold an aggregate of 7,304,286 shares of common stock in at-the-market offerings under the 2014 Sales Agreement, with net proceeds of approximately $19.9 million.

On July 20, 2016, the Company filed a prospectus supplement to move the remaining shares of common stock that previously could have been sold pursuant to the 2014 Sales Agreement under the 2013 Shelf to the 2015 Shelf. On the same date, the Company filed a post-effective amendment to the 2013 Shelf de-registering all remaining securities that could have been offered by the Company pursuant to the 2013 Shelf.

On June 18, 2015, the Company entered into an Underwriting Agreement with Jefferies LLC and Piper Jaffray & Co., acting as representatives of the underwriters named in the 2015 Underwriting Agreement and as joint book-running managers, relating to the issuance and sale of 9,425,000 shares of the Company’s common stock, par value $0.001 per share (the “2015 Offering”). The price to the public in the 2015 Offering was $4.25 per share, and the Underwriters agreed to purchase the shares from the Company pursuant to the 2015 Underwriting Agreement at a price of $3.995 per share. Under the terms of the 2015 Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 1,413,750 shares. The Company issued 10,838,750 shares of common stock pursuant to the 2015 Underwriting Agreement, including shares issuable upon the exercise of the over-allotment option, with net proceeds of approximately $43.1 million, after deducting underwriting discounts and commissions and expenses payable by the Company. The shares were issued pursuant to the 2015 Shelf.

On October 25, 2016, the Company closed the issuance and sale of 10,065,000 shares (the “2016 Offering”) of its common stock. The 2016 Offering was affected pursuant to an Underwriting Agreement (the “2016 Underwriting Agreement”) with Jefferies LLC (the “Representative”), acting as representative of the underwriters named in the 2016 Underwriting Agreement. The price to the public in the 2016 Offering was $2.75 per share, and the underwriters purchased the shares from the Company pursuant to the 2016 Underwriting Agreement at a price of $2.585 per share. The net proceeds to the Company from the 2016 Offering were approximately $25.7 million after deducting underwriting discounts and commissions and expenses payable by the Company. The 2016 Offering was made pursuant to the Company’s 2015 Shelf.

The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018, as supplemented by a prospectus supplement, dated March 16, 2018 (the “2018 Shelf”), that expires on February 22, 2021. This replaces the 2015 Shelf which expired on March 17, 2018.

On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”), pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in “at the market” sales transactions having an aggregate offering price of up to $50,000,000 (the “Shares”). Any shares offered and sold will be issued pursuant to the Company’s 2018 Shelf. During the year ended March 31, 2019, the Company issued 11,631,803 shares of common stock in at-the-market offerings under the sales agreement with net proceeds of $13.2 million.

As of March 31, 2019, the Company had sold an aggregate of 11,631,803 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with net proceeds of approximately $13.2 million. Based on these sales, the Company cannot raise more than an aggregate of $86.4 million future offerings under the 2018 Shelf, including the $36.4 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement. The Company intends to use the net proceeds raised through any at-the-market sales for general corporate purposes, general administrative expenses, and working capital and capital expenditures.

In addition, during the years ended March 31, 2019 and 2018, the Company issued no shares of common stock upon exercise of no warrants, respectively.

During the years ended March 31, 2019 and 2018, the Company issued 622,192 and 500,000 shares of common stock upon exercise of 622,192 and 500,000 stock options, respectively.

Restricted stock units

During the year ended March 31, 2019, the Company issued restricted stock units for an aggregate of 1,916,802 shares of common stock to its employees and directors. These shares of common stock will be issued upon vesting of the restricted stock units.

On August 14, 2018, in connection with the appointment of a new Chief Medical Officer (“CMO”), the Company allocated 160,714 Restricted Stock Units (“RSUs”) outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan.

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity for the year ended March 31, 2019 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		2,035,345		$	2.89
Granted		1,916,802		$	1.18
Vested		(766,187	)	$	2.39
Canceled / forfeited		(1,105,237	)	$	2.33
Unvested at March 31, 2019		2,080,723		$	1.80

Performance-based restricted stock units

On April 24, 2017, the Company issued a Performance-Based Restricted Stock Unit Award for 208,822 shares of common stock (the “PBRSU”) to its newly hired Chief Executive Officer. The PBRSU was issued outside of the 2012 Plan, in the Inducement Award Agreement, as an “inducement award” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of this award are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board of Directors formally approved the vesting criteria for the PBRSU. The vesting of the PBRSU is divided into five separate tranches each with independent vesting criteria. The first four tranches have performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche has a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that ultimately vest for each tranche will range from 0 percent to 120 percent of the target amount, not to exceed 208,822 in aggregate. Based on changes to the Company’s strategy, on December 12, 2018, the Board of Directors formally approved an amendment to the vesting criteria for the PBRSUs. As of March 31, 2019, 100% of the Negative Adjusted EBITDA tranche, or 41,764 shares had vested and 8,352 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones. As of March 31, 2019, no tranches had vested.

Based on the amended PBRSU vesting terms, which the Company believes are probable of being achieved, a Type III modification, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018.

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through March 31, 2019 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		200,470		$	1.88
Granted		—		$	—
Vested		(41,764	)	$	1.88
Canceled / forfeited		—		$	—
Unvested at December 12, 2018		158,706		$	1.88
Impact of modification		—		$	(0.74	)
Granted		—		$	—
Vested		—		$	—
Canceled / forfeited		—		$	—
Unvested at March 31, 2019		158,706		$	1.04

Stock options

During the year ended March 31, 2019 under the 2012 Equity Incentive Plan, 7,049,500 stock options were issued at various exercise prices.

On April 24, 2017, in connection with the appointment of a new CEO, the Company granted 2,088,212 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While granted outside the Company’s 2012 Plan, the terms and conditions of this stock option award are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 14, 2018, in connection with the appointment of a new CMO, the Company allocated 974,694 stock options outside of the 2012 Plan. The Company intends for these to be “inducement awards” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of these awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods.

The following table summarizes stock option activity for the year ended March 31, 2019:

	Options Outstanding			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2018		10,132,312		$	4.01	$	591,082
Options granted		8,024,194		$	1.29	$	—
Options canceled		(5,495,050	)	$	4.37	$	—
Options exercised		(622,192	)	$	0.08	$	561,591
Outstanding at March 31, 2019		12,039,264		$	2.24	$	—
Vested and Exercisable at March 31, 2019		3,810,831		$	3.68	$	—

The weighted-average remaining contractual term of stock options exercisable and outstanding at March 31, 2019 was approximately 6.9 years.

Employee Stock Purchase Plan

In June 2016, our Board of Directors adopted, and in August 2016 stockholders subsequently approved, the 2016 Employee Stock Purchase Plan (“ESPP”). The Company reserved 1,500,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 per employee per year or 10,000 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. During the year ended March 31, 2019, 96,385 shares were issued under the ESPP. At March 31, 2019, there were 1,188,718 shares remaining available for the purchase under the ESPP.

Warrants

From 2012 to 2014, the Company issued a total of 650,000 warrants to purchase common stock, in connection with consulting agreements, at prices ranging from $1.70 to $3.24, with lives ranging from two to five years, to be earned over service periods of up to six months. During the years ended March 31, 2019 and 2018, no warrants held by consultants were exercised. As of March 31, 2019, none of these warrants are outstanding.

Additionally, during September 2014, the Company issued 50,000 warrants to purchase common stock, at a price of $7.62 with a life of five years to a consultant in recognition of services previously provided. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. As of December 31, 2014, the full amount of the warrants related to these services, approximately $237,000 had been recognized.

In November 2014, in connection with a consulting agreement, the Company issued 145,000 warrants to purchase common stock, at a price of $6.84, with a life of five years, to be earned over a seventeen month service period ended on March 31, 2016. The final number of vested warrant shares was 95,000, based on management’s judgment of the satisfaction of specific performance metrics. The fair value of the warrants was estimated to be approximately $74,000, which was revalued and amortized over the term of the consulting agreement. These warrants were classified as equity instruments because they do not contain any anti-dilution provisions. The Black-Scholes model, using a volatility rate of 73.4% and a risk-free interest rate factor of 1.21%, was used to determine the value as of March 31, 2016. The Company recognized approximately $6,000 during the year ended March 31, 2016 related to these services. As of March 31, 2016, these warrants were fully expensed.

The following table summarizes warrant activity for the year ended March 31, 2019:

	Warrants			Weighted-Average Exercise Price
Balance at March 31, 2018		220,000		$	7.19
Granted		—		$	—
Expired / Canceled		(75,000	)	$	7.36
Exercised		—		$	—
Balance at March 31, 2019		145,000		$	7.11

The warrants outstanding at March 31, 2019 are exercisable at prices of $6.84 and $7.62 per share and have a weighted average remaining term of approximately 0.53 years.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at March 31, 2019:

Common stock warrants outstanding			145,000
Common stock options outstanding and reserved under the 2012 Plan			8,976,358
Common stock reserved under the 2012 Plan			13,464,720
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,188,718
Restricted stock units outstanding under the 2012 Plan			1,920,009
Common stock options outstanding and reserved under the Incentive Award Agreement			3,062,906
Restricted stock units outstanding under the Incentive Award Agreement			160,714
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total			29,077,131

Commitments and Contingencies

12 Months Ended

Mar. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. Commitments and Contingencies

Operating leases

Since July 2012, the Company has leased its main facilities at 6275 Nancy Ridge Drive, San Diego, CA 92121. The lease, as amended in 2013, 2015, 2016, 2018, and 2019, consisted of approximately 45,580 rentable square feet containing laboratory, clean room and office space. Monthly rental payments are currently approximately $120,000 per month with 3% annual escalators. The lease term for 14,685 of the total rentable square footage was amended to accelerate the expiration date from December 15, 2018 to October 31, 2018. On November 30, 2018, the Company agreed to extend the term for the remainder of the total rentable square footage under the lease from August 31, 2021 to August 31, 2024 in exchange for $500,000 of landlord funded tenant improvements and a rescission of its option to terminate the lease on or after September 1, 2019 with 9 months prior written notice.

The Company also previously leased a second facility from February 1, 2015 through January 31, 2018 consisting of 5,803 rentable square feet of office and lab space located at 6310 Nancy Ridge Drive, San Diego, CA 92121, with a monthly rent of $12,000 commencing on April 1, 2015, which increased by 3% each 12-month anniversary of the 36 month lease.

The Company records rent expense on a straight-line basis over the life of the leases and records the excess of expense over the amounts paid as deferred rent. In addition, one of the leases provides for certain improvements made for the Company’s benefit to be funded by the landlord. Such costs, totaling approximately $518,000 to date, have been capitalized as fixed assets and included in deferred rent. As a result of the Company’s lease amendment, which extends the term of the lease from August 31, 2021 to August 31, 2024, the landlord agreed to fund up to $500,000 in additional tenant improvements, which have not been capitalized or included in deferred rent

Rent expense was approximately $1,173,000 and $1,458,000 for the years ended March 31, 2019 and 2018, respectively.

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2019, are as follows (in thousands):

Fiscal year ended March 31, 2020	$	1,084
Fiscal year ended March 31, 2021		1,116
Fiscal year ended March 31, 2022		1,158
Fiscal year ended March 31, 2023		1,183
Fiscal year ended March 31, 2024		1,218
Thereafter		514
Total	$	6,273

Legal matters

In addition to commitments and obligations in the ordinary course of business, the Company may be subject, from time to time, to various claims and pending and potential legal actions arising out of the normal conduct of its business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing litigation contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation against it may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability.

The Company regularly reviews contingencies to determine the adequacy of its accruals and related disclosures. During the period presented, the Company has not recorded any accrual for loss contingencies associated with such claims or legal proceedings; determined that an unfavorable outcome is probable or reasonably possible; or determined that the amount or range of any possible loss is reasonably estimable. However, the outcome of legal proceedings and claims brought against the Company is subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against the Company in a reporting period, the Company’s consolidated financial statements for that reporting period could be materially adversely affected.

As of March 31, 2019, the Company had no claims outstanding.

Licensing Agreements and Research Contracts

12 Months Ended

Mar. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Licensing Agreements and Research Contracts

7. Licensing Agreements and Research Contracts

University of Missouri

In March 2009, the Company entered into a license agreement with the Curators of the University of Missouri to in-license certain technology and intellectual property relating to self-assembling cell aggregates and to intermediate cellular units. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales of covered tissue products, and of the fair market value of covered tissues transferred internally for use in the Company’s commercial service business, depending on the level of net sales achieved by the Company each year. The Company paid minimum annual royalties of $25,000 in January 2018, and January 2019 for their respective calendar years, which is credited against royalties due during the subsequent twelve months. No payments have been made in excess of the minimum annual royalties in the years ended March 31, 2019 and 2018.The license agreement terminates upon expiration of the patents licensed and is subject to certain conditions as defined in the license agreement, which are expected to expire after 2029.

In March 2010, the Company entered into a license agreement with the Curators of the University of Missouri to in-license certain technology and intellectual property relating to engineered biological nerve grafts. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University of Missouri royalties ranging from 1% to 3% of net sales of covered tissue products depending on the level of net sales achieved by the Company each year. The license agreement terminates upon expiration of the patents licensed and is subject to certain conditions as defined in the license agreement. No payments have been made in the years ended March 31, 2019 and 2018.

Clemson University

In May 2011, the Company entered into a license agreement with Clemson University Research Foundation to in-license certain technology and intellectual property relating to ink-jet printing of viable cells. The Company received the exclusive worldwide rights to commercialize products comprising this technology for all fields of use. The Company is required to pay the University royalties ranging from 1.5% to 3% of net sales of covered tissue products and the fair market value of covered tissues transferred internally for use in the Company’s commercial service business, depending on the level of net sales reached each year. The license agreement terminates upon expiration of the patents licensed, which is expected to expire in May 2024, and is subject to certain conditions as defined in the license agreement. Minimum annual royalty payments of $20,000 were due for each of the two years beginning with calendar 2014, and $40,000 per year beginning with calendar 2016. The annual minimum royalty is creditable against royalties owed during the same calendar year.

Capitalized license fees consisted of the following (in thousands):

	March 31, 2019			March 31, 2018
License fees	$	218		$	218
Less accumulated amortization		(81	)		(67	)
License fees, net	$	137		$	151

The above license fees, net of accumulated amortization, are included in Other Assets in the accompanying balance sheets and are being amortized over the life of the related patents. Amortization expense of licenses was approximately $14,000 and $13,600 for the years ended March 31, 2019 and 2018, respectively. At March 31, 2019, the weighted average remaining amortization period for all licenses was approximately 11 years. The annual amortization expense of licenses for the next five years is estimated to be approximately $14,000 per year.

Income Taxes

12 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows as of March 31, 2019 and March 31, 2018 (in thousands):

	March 31, 2019			March 31, 2018
Deferred tax assets:
Net operating loss carry forwards	$	—		$	—
Research and development credits		—			—
Depreciation and amortization		28			25
Accrued expenses and reserves		886			1,050
Stock compensation		3,941			3,753
Other, net		20			8
Total deferred tax assets		4,875			4,836
Valuation allowance		(4,875	)		(4,836	)
	$	—		$	—

A full valuation allowance has been established to offset the deferred tax assets as management cannot conclude that realization of such assets is more likely than not. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of our net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. We have not completed an analysis to determine whether any such limitations have been triggered as of March 31, 2019. Until this analysis is completed, we have removed the deferred tax assets related to net operating losses and research credits from our deferred tax asset schedule. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact its effective tax rate. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. The valuation allowance increased by approximately $39,000 and decreased by approximately $3.2 million for the years ended March 31, 2019 and 2018, respectively.

The Company had federal and state net operating loss carryforwards of approximately $170.3 million and $49.2 million, respectively, as of March 31, 2019. The federal net operating loss carryforward generated during the year ended March 31, 2019 of approximately $24.1 million will carryforwards indefinitely and be available to offset up to 80% of future taxable income each year. Federal net operating losses generated previously will begin to expire in 2028, unless previously utilized. The state net operating loss carryforwards (“NOLs”) will begin to expire in 2028, unless previously utilized.

The Company had federal and state research tax credit carryforwards of approximately $4.0 million and $3.6 million at March 31, 2019, respectively. The federal research tax credit carryforwards begin expiring in 2028. The state research tax credit carryforwards do not expire.

The Tax Cuts and Jobs Act (“the Act”) was enacted on December 22, 2017. The Act (i) reduces the US federal corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, an (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The Act also impacts the valuation of a company’s deferred tax assets and liabilities. The Company applied the guidance in Staff Accounting Bulletin No. 118 when accounting for the enactment-date effects of the Act in the year ended March 31, 2019.

As of December 31, 2017, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future (which is generally 21%), by recording a provisional amount of $2.7 million, which was fully offset by the valuation allowance.

Due to the deficit in post-1986 E&P from the foreign subsidiary, there was no increase in income tax expense related to the one-time transition tax. As of March 31, 2019, the Company has completed its accounting for the Act and determined that no adjustment was necessary to the provisional amounts.

The Company did not record any accruals for income tax accounting uncertainties for the year ended March 31, 2019.

The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company did not accrue either interest or penalties from inception through March 31, 2019.

The Company does not expect its unrecognized tax benefits to significantly increase or decrease within the next 12 months.

The Company is subject to tax in the United States and in various state jurisdictions. As of March 31, 2019, the Company’s tax years from inception are subject to examination by the tax authorities due to the generation of net operating losses. The Company is not currently under examination by any jurisdiction.

Concentrations

12 Months Ended

Mar. 31, 2019

Risks And Uncertainties [Abstract]

Concentrations

9. Concentrations

Credit risk and significant customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company maintains cash balances at various financial institutions primarily located within the United States. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. Balances may exceed federally insured limits. The Company has not experienced losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

The Company is also potentially subject to concentrations of credit risk in its revenues and accounts receivable. Because it is in the early commercial stage, the Company’s revenues to date have been derived from a relatively small number of customers and collaborators. However, the Company has not historically experienced any accounts receivable write-downs and management does not believe significant credit risk exists as of March 31, 2019.

Related Parties

12 Months Ended

Mar. 31, 2019

Related Parties

10. Related Parties

From time to time, the Company will enter into an agreement with a related party in the ordinary course of its business and on terms and conditions it believes are as fair as those it offers and receives from independent third parties. These agreements are ratified by the Company’s Board of Directors or a committee thereof pursuant to its related party transaction policy.

In August 2017, the Company entered into a services agreement with Cirius Therapeutics, Inc. (“Cirius”), an entity for which Robert Baltera, Jr., a director of the Company, serves as Chief Executive Officer. Under this agreement and its amendments, the Company has provided ExVive™ Liver Tissue Services for Cirius in the amount of $281,000 to date, of which $120,000 and $161,000 was recognized as revenue in the years ended March 31, 2019 and March 31, 2018, respectively.

In November 2017, the Company entered into a collaboration agreement with Viscient Biosciences (“Viscient”), an entity for which Keith Murphy, a former director and former Chief Executive Officer of the Company, serves as Chief Executive Officer. Under this agreement and its amendments, the Company provided research services amounting to $358,000 recognized as revenue in the year ended March 31, 2018. In September 2018, Viscient purchased study materials from Organovo in the amount of $2,000 to date, pursuant to the terms of a Quote, of which $2,000 was recognized as revenue in the year ended March 31, 2019. In November 2018, Viscient executed a Quote to purchase research services from Organovo in the amount of $142,000, of which $42,000 was recognized as revenue in the year ended March 31, 2019. Additionally, Viscient purchased primary human cell-based products from our subsidiary, Samsara, in the amount of $165,000 to date, pursuant to the terms of multiple Quotes entered into throughout the 2018 and 2019 fiscal years, of which $96,000 and $14,000 were recognized as revenue in the years ended March 31, 2019 and March 31, 2018, respectively.

Defined Contribution Plan

12 Months Ended

Mar. 31, 2019

Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]

Defined Contribution Plan

11. Defined Contribution Plan

The Company has a defined contribution 401(k) plan covering substantially all employees. During the year ended March 31, 2015, the 401(k) plan was amended (the “Amended Plan”) to include an employer matching provision. Under the terms of the Amended Plan, the Company will make matching contributions on up to the first 6% of compensation contributed by its employees. Amounts expensed under the Company’s 401(k) plan for the years ended March 31, 2019 and 2018 were approximately $240,000 and $337,000, respectively.

Recent Accounting Pronouncements

12 Months Ended

Mar. 31, 2019

Accounting Changes And Error Corrections [Abstract]

Recent Accounting Pronouncements

12. Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.

Adoption of New Accounting Pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which supersedes most existing revenue recognition guidance in GAAP, including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. The Company adopted this standard on its effective date, April 1, 2018, under the modified retrospective method of adoption. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of April 1, 2018 did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. See “Note 2. Summary of Significant Accounting Policies” for further discussion. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after April 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to April 1, 2018 are described in “Note 1. Description of Business and Summary of Significant Accounting Policies”. Adoption of this ASC did not have a material impact on the Company’s financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for the Company on April 1, 2018. The Company adopted this standard using the retrospective transition method by restating its condensed consolidated statements of cash flows to include restricted cash of $0.1 million in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the twelve months ended March 31, 2018, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows.

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on the Company’s financial statements.

In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which resulted in a minimal impact to its financial statements. See “Note 8. Income Taxes” for more information.

Recent Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the lease guidance under ASC 840 – Leases. The new accounting standard requires an entity to recognize right-of-use assets and corresponding lease liabilities on the balance sheet for all leases with terms of more than 12 months and to disclose key information about leasing arrangements. This new guidance is effective for the Company on April 1, 2019, with early adoption permitted in any interim or annual period. The Company will adopt ASU 2016-02 on April 1, 2019 and will elect the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and will not restate prior periods. The Company will elect the package of practical expedients permitted under the transition guidance, but not the hindsight practical expedient. As a result of the adoption, the Company will record right-of-use assets and liabilities of approximately $4.5 million and $5.0 million, respectively, on its Consolidated Balance Sheet as of April 1, 2019, primarily associated with its operating leases.

In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. These amendments simplify the accounting for certain financial instruments with down round features. The amendments require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger within equity. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of this guidance will have no impact on the Company’s financial statements as the Company’s only derivative liabilities were all exercised or expired as of March 31, 2017.

In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (“Topic 220”), which allows stranded tax effects resulting from the Tax Cuts and Jobs Act to be reclassified from accumulated other comprehensive income to retained earnings. The amendment only relates to the reclassification of the income tax effects of the Tax Cuts and Jobs Act; thus, the underlying guidance relating to the effect of a change in tax laws be included in income from continuing operations is not affected. The amendments in Topic 220 are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-02 are not expected to have a significant impact on the Company’s financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. This new guidance is effective for the Company on April 1, 2019. The requirements of ASU 2018-07 are not expected to have a significant impact on the Company’s financial statements.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606, which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. The amendments in this update provide more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from this amendment are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance is effective for the Company on April 1, 2020. The Company is currently evaluating the impact that this guidance will have on its financial statements.

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Nature of operations and basis of presentation	Nature of operations and basis of presentation Organovo Holdings, Inc. (“Organovo Holdings,” “we,” “us,” “our,” “the Company” and “our Company”) is a biotechnology company pioneering the development of bioprinted human tissues that emulate human biology and disease. Initially, we are developing our in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. Our objective is to serve as a ‘bridge-to-transplant’ for these patients, with an ultimate goal of delaying or reducing the overall need for transplant. The Company’s program focused on an orphan disease known as Alpha-1-antitrypsin deficiency (“A1AT”), received the U.S. Food and Drug Administration’s (“FDA”) orphan drug designation in December 2017. We are also utilizing our foundational ability to isolate highly specialized human cells to build robust, functional human tissues by creating a range of novel preclinical in vitro disease modeling platforms, including a broad set of non-alcoholic fatty liver disease (“NAFLD”) and non-alcoholic steatohepatitis (“NASH”) conditions. Our clients can access these diseased tissue platforms through collaborative, revenue-generating agreements. Except where specifically noted or the context otherwise requires, references to “Organovo Holdings,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., Samsara Sciences, Inc., and Organovo UK Ltd in March 2018, the U.K. operations were combined with Organovo, Inc.’s operations. The Company’s activities are subject to significant risks and uncertainties including failing to successfully develop products and services based on its technology, failing to achieve regulatory approvals for its therapeutic candidates, and failing to achieve the market acceptance necessary to generate sufficient revenues to achieve and sustain profitability.
Reclassification of prior year presentation	Reclassification of prior year presentation As a result of the adoption of the new accounting standard associated with clarifying presentation and classification in the statement of cash flows, certain reclassifications have been made to the prior period financial statements to conform with the current period presentation. These reclassifications did not have any effect on previously reported cash flows, net loss, or financial position.
Nasdaq listing	Nasdaq listing On August 8, 2016, the Company moved its stock exchange listing to the Nasdaq Global Market, under the “ONVO” ticker symbol. From July 11, 2013 through August 5, 2016, the Company listed its shares on the NYSE MKT. Prior to July 11, 2013, the Company’s shares were quoted on the OTC QX.
Liquidity	Liquidity As of March 31, 2019, the Company had cash and cash equivalents of approximately $36.5 million and restricted cash of less than $0.1 million. The restricted cash was pledged as collateral for two letters of credit the Company is required to maintain as security deposits under the terms of the leases of its facilities. The Company had an accumulated deficit of approximately $260.8 million. The Company also had negative cash flows from operations of approximately $20.4 million during the year ended March 31, 2019. Through March 31, 2019, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, grants, and licenses. During the year ended March 31, 2019, the Company issued 11,631,803 shares of its common stock through its ATM facility and received net proceeds of approximately $13.2 million. Based on its current operating plan and available cash resources, the Company believes it has sufficient resources to fund its business for at least the next twelve months. The Company will need additional capital to further fund the development of its proprietary platform to produce and study living tissues focusing on critical unmet medical needs in the liver disease space. The Company intends to cover its future operating expenses through cash on hand, through revenue derived from research service agreements, product sales, collaborative agreements, grants and license payments, and through the issuance of additional equity or debt securities. Depending on market conditions, we cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. Having insufficient funds may require us to delay, scale back, or eliminate some or all of our development programs or relinquish rights to our technology on less favorable terms than we would otherwise choose. Failure to obtain adequate financing could eventually adversely affect our ability to operate as a going concern. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.
Use of estimates	Use of estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the consolidated financial statements include those assumed in revenue recognition, the valuation of stock-based compensation expense, and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions.
Financial instruments	Financial instruments For certain of the Company’s financial instruments, including cash and cash equivalents, inventory, prepaid expenses and other assets, accounts payable, accrued expenses, deferred revenue, and capital lease obligations, the carrying amounts are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.
Foreign Currency	Foreign Currency The functional currency of our U.K. operations was the pound sterling. Accordingly, all assets and liabilities of this subsidiary were translated to US dollars based on the applicable exchange rate on the balance sheet date. Revenue and expense components were translated to US dollars at the exchange rates in effect during the period. Gains and losses resulting from foreign currency translation are reported as a separate component of accumulated other comprehensive income or loss in the equity section of our consolidated balance sheets. Foreign currency transaction gains and losses, which are primarily the result of remeasuring United States dollar-denominated receivables and payables, are recorded in our Consolidated Statements of Operations and Other Comprehensive Loss. For the years ended March 31, 2019 and 2018, we recognized foreign currency translation losses of approximately $0 and $1,000, respectively. As of March 31, 2019 and 2018, we realized $0 and $11,000 of cumulative foreign currency translation losses as Other Expense on the Consolidated Statement of Operations and Other Comprehensive Loss for the years ending March 31, 2019 and 2018, respectively. No further foreign currency translation losses will be recorded as the U.K. operations have been combined with Organovo, Inc.’s operations as of March 31, 2018.
Restricted cash	Restricted cash As of March 31, 2019 and 2018, the Company had approximately $79,000 and $127,000 of restricted cash, respectively, deposited with a financial institution. The entire amount is held in certificates of deposit to support a letter of credit agreement related to the Company’s facility lease.
Inventory	Inventory Inventories are stated at the lower of the cost or net realizable value (first-in, first-out). Inventory at March 31, 2019 consists of approximately $361,000 in raw materials, approximately $0 in work-in-process inventory, and approximately $129,000 in finished goods net of reserve. Inventory at March 31, 2018 consisted of approximately $578,000 in raw materials, approximately $26,000 in work-in progress inventory, and approximately $238,000 in finished goods net of reserve.
Fixed assets and depreciation	Fixed assets and depreciation Property and equipment are carried at cost. Expenditures that extend the life of the asset are capitalized and depreciated. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets or, in the case of leasehold improvements, over the lesser of the useful life of the related asset or the remaining lease term. The estimated useful lives of the fixed assets range between one and seven years.
Impairment of long-lived assets	Impairment of long-lived assets In accordance with authoritative guidance, the Company reviews its long-lived assets, including property and equipment and other assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates whether future undiscounted net cash flows will be less than the carrying amount of the assets and adjusts the carrying amount of its assets to fair value. Management has determined that no impairment of long-lived assets occurred as of March 31, 2019.
Research and development	Research and development Research and development expenses, including direct and allocated expenses, consist of independent research and development costs, as well as costs associated with sponsored research and development. Research and development costs are expensed as incurred.
Income taxes	Income taxes Deferred income taxes are recognized for the tax consequences in future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
Revenue recognition	Revenue recognition The Company generates revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. Billings to customers or payments received from customers are included in deferred revenue on the balance sheet until all revenue recognition criteria are met. As of March 31, 2019 and 2018, the Company had approximately $525,000 and $687,000, respectively, in deferred revenue related to its research service agreements, collaborative agreements, and licenses within the scope of Topic 606. In the twelve months ended March 31, 2019 the Company recognized revenue on approximately $178,000 that had been recorded as deferred revenue at March 31, 2018. Effective April 1, 2018, the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, the Company recognizes revenue when (or as) the promised services are transferred to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concludes are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the performance obligation(s) are satisfied. At contract inception, the Company assesses the goods or services promised within each contract, assesses whether each promised good or service is distinct and identifies those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Service revenues The Company’s service-based business, Organovo, Inc., utilizes its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contain multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which are satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer does not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service can be customized for each customer, it is not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilizes point-in-time recognition under Topic 606. For service contracts, the Company allocates the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts is a fixed consideration. Product sales, net The Company’s product-based business, Samsara Sciences, Inc., produces cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognizes product revenue when the performance obligation is satisfied, which is at the point in time the customer obtains control of the Company’s product, typically upon delivery. Product revenues are recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration does not differ materially from its historical practices. Variable consideration is estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflects the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. The Company provides no right of return to its customers except in cases where a customer obtains authorization from the Company for the return. To date, there have been no product returns. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust its estimates accordingly. Collaborative research, development, and licenses The Company enters into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzes whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC 808, Collaborative Arrangements (“Topic 808”). The Company considers a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are determinable stand-alone prices, and whether any licenses are functional or symbolic. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provide the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company has determined the intellectual property license is not distinct from the continued support promised under the agreement and is therefore a single combined performance obligation. The Company recognizes revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation will not be fully satisfied until the end of the contract. For the year ended March 31, 2019, all collaborations and licenses revenue was within the scope of Topic 606 and recognized accordingly. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenues In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company has concluded this government grant is not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company has concluded this government grant does not meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition does not apply, as the Company is a business entity and the grant is with a governmental agency. Revenues from the grant are based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue is recognized when the Company incurs expenses that are related to the grant. The Company believes this policy is consistent with the overarching premise in Topic 606, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in the ASC. The Company believes the recognition of revenue as costs are incurred and amounts become earned/realizable is analogous to the concept of transfer of control of a service over time under ASC 606. Revenue recognized under this grant was approximately $587,000 and $554,000 during the years ended March 31, 2019 and 2018, respectively.
Cost of revenues	Cost of revenue The Company reported $0.5 million and $1.0 million in cost of revenue for the years ended March 31, 2019 and 2018, respectively. Cost of revenues consists of our costs related to manufacturing and delivering our product and service revenue.
Stock-based compensation	Stock-based compensation The Company accounts for stock-based compensation in accordance with the Financial Accounting Standards Board’s ASC Topic 718, Compensation — Stock Compensation, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant). The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity-based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Comprehensive income (loss)	Comprehensive income (loss) Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended March 31, 2019 and 2018, the comprehensive loss was materially equal to the net loss and consisted of net loss and foreign currency translation. As of March 31, 2019, unrealized foreign currency translation previously recorded in other comprehensive loss was realized and recorded to other expense.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options and warrants, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the years ended March 31, 2019 and 2018 as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share were approximately 14.4 million and 12.6 million for the years ended March 31, 2019 and 2018, respectively.

Recent Accounting Pronouncements (Policies)

12 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Recent Accounting Pronouncements

Adoption of New Accounting Pronouncements

Recent Accounting Pronouncements Not Yet Adopted

Fixed Assets (Tables)

12 Months Ended

Mar. 31, 2019

Property Plant And Equipment [Abstract]

Schedule of Fixed Assets

Fixed assets consisted of the following (in thousands):

	March 31, 2019			March 31, 2018
Construction in Progress	$	47		$	—
Laboratory equipment	$	3,690		$	3,695
Leasehold improvements		1,809			2,177
Computer software and equipment		645			656
Furniture and fixtures		213			319
Vehicles		9			9
Fixed Assets, gross		6,413			6,856
Less accumulated depreciation		(4,581	)		(4,068	)
Fixed Assets, net	$	1,832		$	2,788

Accrued Expenses (Tables)

12 Months Ended

Mar. 31, 2019

Payables And Accruals [Abstract]

Summary of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	March 31, 2019		March 31, 2018
Accrued compensation	$	2,160	$	2,735
Accrued legal and professional fees		152		99
Other accrued expenses		237		507
	$	2,549	$	3,341

Stockholders' Equity (Tables)

12 Months Ended

Mar. 31, 2019

Class Of Stock [Line Items]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense for all stock awards consists of the following (in thousands):

	Year Ended March 31, 2019		Year Ended March 31, 2018
Research and development	$	911	$	1,174
General and administrative	$	4,282	$	5,729
Total	$	5,193	$	6,903

Fair Value of Employee Stock Options

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Year Ended March 31, 2019			Year Ended March 31, 2018
Dividend yield		—			—
Volatility		72.99	%		76.86	%
Risk-free interest rate		2.75	%		1.81	%
Expected life of options	6.00 years			6.00 years
Weighted average grant date fair value	$	0.84		$	1.73

Fair Value of Employee Stock Purchase Plan

The fair value of ESPP shares was estimated at the purchase period commencement date using the following weighted average assumptions:

	Year Ended March 31, 2019		Year Ended March 31, 2018
Dividend yield		—		—
Volatility	43.7 - 80.2%		43.0% - 74.7%
Risk-free interest rate	1.85 - 2.52%		0.79% - 1.85%
Expected term	6 months		6 months
Grant date fair value	$ 0.29 - $0.45		$ 0.30 - $1.04

Summary of Stock Option Activity

The following table summarizes stock option activity for the year ended March 31, 2019:

	Options Outstanding			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2018		10,132,312		$	4.01	$	591,082
Options granted		8,024,194		$	1.29	$	—
Options canceled		(5,495,050	)	$	4.37	$	—
Options exercised		(622,192	)	$	0.08	$	561,591
Outstanding at March 31, 2019		12,039,264		$	2.24	$	—
Vested and Exercisable at March 31, 2019		3,810,831		$	3.68	$	—

Summary of Warrant Activity

The following table summarizes warrant activity for the year ended March 31, 2019:

	Warrants			Weighted-Average Exercise Price
Balance at March 31, 2018		220,000		$	7.19
Granted		—		$	—
Expired / Canceled		(75,000	)	$	7.36
Exercised		—		$	—
Balance at March 31, 2019		145,000		$	7.11

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following at March 31, 2019:

Common stock warrants outstanding			145,000
Common stock options outstanding and reserved under the 2012 Plan			8,976,358
Common stock reserved under the 2012 Plan			13,464,720
Common stock reserved under the 2016 Employee Stock Purchase Plan			1,188,718
Restricted stock units outstanding under the 2012 Plan			1,920,009
Common stock options outstanding and reserved under the Incentive Award Agreement			3,062,906
Restricted stock units outstanding under the Incentive Award Agreement			160,714
Performance-based restricted stock units outstanding under the Incentive Award Agreement			158,706
Total			29,077,131

Restricted stock units (RSUs) [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity

A summary of the Company’s restricted stock unit (not including performance-based restricted stock units) activity for the year ended March 31, 2019 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		2,035,345		$	2.89
Granted		1,916,802		$	1.18
Vested		(766,187	)	$	2.39
Canceled / forfeited		(1,105,237	)	$	2.33
Unvested at March 31, 2019		2,080,723		$	1.80

Performance-Based Restricted Stock Units [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity

A summary of the Company’s performance-based restricted stock unit activity from March 31, 2018 through March 31, 2019 is as follows:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2018		200,470		$	1.88
Granted		—		$	—
Vested		(41,764	)	$	1.88
Canceled / forfeited		—		$	—
Unvested at December 12, 2018		158,706		$	1.88
Impact of modification		—		$	(0.74	)
Granted		—		$	—
Vested		—		$	—
Canceled / forfeited		—		$	—
Unvested at March 31, 2019		158,706		$	1.04

Commitments and Contingencies (Tables)

12 Months Ended

Mar. 31, 2019

Commitments And Contingencies Disclosure [Abstract]

Future Minimum Annual Operating Lease Payments

Future minimum rental payments required under operating leases that have initial or remaining non-cancelable lease terms in excess of one year as of March 31, 2019, are as follows (in thousands):

Fiscal year ended March 31, 2020	$	1,084
Fiscal year ended March 31, 2021		1,116
Fiscal year ended March 31, 2022		1,158
Fiscal year ended March 31, 2023		1,183
Fiscal year ended March 31, 2024		1,218
Thereafter		514
Total	$	6,273

Licensing Agreements and Research Contracts (Tables)

12 Months Ended

Mar. 31, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Capitalized License Fees

Capitalized license fees consisted of the following (in thousands):

	March 31, 2019			March 31, 2018
License fees	$	218		$	218
Less accumulated amortization		(81	)		(67	)
License fees, net	$	137		$	151

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Summary of Net Deferred Tax Assets

Significant components of the Company’s net deferred tax assets are as follows as of March 31, 2019 and March 31, 2018 (in thousands):

	March 31, 2019			March 31, 2018
Deferred tax assets:
Net operating loss carry forwards	$	—		$	—
Research and development credits		—			—
Depreciation and amortization		28			25
Accrued expenses and reserves		886			1,050
Stock compensation		3,941			3,753
Other, net		20			8
Total deferred tax assets		4,875			4,836
Valuation allowance		(4,875	)		(4,836	)
	$	—		$	—

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 36,477,000	$ 43,726,000
Accumulated deficit	(260,755,000)	(234,120,000)
Cash flow from operations	$ 20,375,000	$ 28,857,000
Issuance of common stock	124,015,429	111,032,957
Gross proceeds from sale of common stock shares	$ 13,327,000	$ 9,381,000
Foreign currency translation adjustment	0	(1,000)
Cumulative foreign currency translation losses	0	(11,000)
Restricted cash	79,000	127,000
Inventory of raw materials, net of reserves	361,000	578,000
Inventory of work-in-process, net of reserves	0	26,000
Inventory of finished goods, net of reserves	$ 129,000	238,000
Estimated useful life of the fixed assets	The estimated useful lives of the fixed assets range between one and seven years.
Impairment of long-lived assets	$ 0
Deferred revenue	525,000	668,000
Revenue recognized		178,000,000
Revenue recognized under grants	3,091,000	4,603,000
Cost of revenue	500,000	1,000,000
Dilutive effect	$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share	14,400,000	12,600,000
Grants [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants	$ 587,000	$ 554,000
NIH Research Grants Two [Member] \| Grants [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants	587,000,000	554,000,000
Research and Development Services [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Deferred revenue	$ 525,000	$ 687,000
At-The-Market Facility [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock	11,631,803
Gross proceeds from sale of common stock shares	$ 13,200,000
Maximum [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 100,000
Maturity of highly liquid investment	90 days
Useful life of fixed assets, range	7 years
Minimum [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Useful life of fixed assets, range	1 year

Fixed Assets - Schedule of Fixed Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Property Plant And Equipment [Abstract]
Construction in Progress	$ 47	$ 0
Laboratory equipment	3,690	3,695
Leasehold improvements	1,809	2,177
Computer software and equipment	645	656
Furniture and fixtures	213	319
Vehicles	9	9
Fixed Assets, gross	6,413	6,856
Less accumulated depreciation	(4,581)	(4,068)
Fixed Assets, net	$ 1,832	$ 2,788

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Payables And Accruals [Abstract]
Accrued compensation	$ 2,160	$ 2,735
Accrued legal and professional fees	152	99
Other accrued expenses	237	507
Accrued expenses	$ 2,549	$ 3,341

Collaborative Research, Development, and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended			12 Months Ended
	May 31, 2018	Sep. 30, 2017	Apr. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				$ 3,091,000	$ 4,603,000
Non-exclusive patent license agreement annual fee				482,000	1,030,000
April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement term			2 years
Proceeds from Non-exclusive patent annual license fee	$ 75,000		$ 75,000
Collaborations and Licenses [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				171,000	422,000
Collaborations and Licenses [Member] \| April 2015 Research Collaboration Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				0	150,000
Collaborations and Licenses [Member] \| June 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				0	65,000
Collaborations and Licenses [Member] \| December 2016 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				39,000	39,000
Collaborations and Licenses [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				75,000	75,000
Collaborations and Licenses [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member] \| Up-front Payment Received [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues				57,000	43,000
Collaborations and Licenses [Member] \| September 2017 Agreement [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Total Revenues		$ 50,000		$ 0	$ 50,000
License [Member] \| April 2017 Non-exclusive Research Affiliation Collaborative [Member]
Collaborative Arrangements and Noncollaborative Arrangement Transactions [Line Items]
Non-exclusive patent license agreement annual fee			$ 75,000

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 5,193	$ 6,903
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	911	1,174
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,282	$ 5,729

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	12 Months Ended
	Mar. 31, 2019 USD ($)
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 7,439,000
Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	5 months
Unrecognized stock-based compensation expense	$ 10,000
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 8 months 26 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 5 months 26 days
Unrecognized stock-based compensation expense	$ 3,234,000
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	4 years 25 days
Unrecognized stock-based compensation expense	$ 136,000

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) - $ / shares	1 Months Ended	12 Months Ended
	Nov. 30, 2014	Mar. 31, 2019	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Dividend yield		0.00%	0.00%
Volatility	73.40%	72.99%	76.86%
Risk-free interest rate	1.21%	2.75%	1.81%
Expected life of options		6 years	6 years
Weighted average grant date fair value		$ 0.84	$ 1.73

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected term	6 years	6 years
Grant date fair value	$ 0.84	$ 1.73
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Volatility, Minimum	43.70%	43.00%
Volatility, Maximum	80.20%	74.70%
Risk-free interest rate, Minimum	1.85%	0.79%
Risk-free interest rate, Maximum	2.52%	1.85%
Expected term	6 months	6 months
2016 Employee Stock Purchase Plan [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 0.29	$ 0.30
2016 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Grant date fair value	$ 0.45	$ 1.04

Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)			12 Months Ended		39 Months Ended
	Oct. 25, 2016	Jun. 18, 2015	Mar. 31, 2019	Mar. 31, 2018	Mar. 17, 2018	Aug. 14, 2018	Jul. 31, 2018	Mar. 16, 2018	Apr. 24, 2017	Aug. 31, 2015	Feb. 27, 2015	Aug. 31, 2013	Jul. 17, 2013	Jan. 31, 2012	May 31, 2008
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares			622,192	500,000
Issuance of common stock			124,015,429	111,032,957
Common stock, par value			$ 0.001	$ 0.001
Gross proceeds from sale of common stock shares			$ 13,327,000	$ 9,381,000
Issuance of common stock from warrant exercises, net, Shares			0	0
Warrants exercised			0	0
Stock option exercised			622,192	500,000
Equity Offering Sales Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares				5,307,105
Value of shares sold under equity distribution agreement				$ 9,200,000	$ 19,900,000
Equity sales agreement expiration date			Mar. 17, 2018
Issuance of common stock					7,304,286
2015 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Stock option exercisable, period		30 days
Additional common stock issued on exercise of option by underwriters		1,413,750
2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date				Feb. 22, 2021
IPO [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount											$ 190,000,000		$ 100,000,000
Secondary Offering [Member] \| 2015 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares		10,838,750
Common stock, par value		$ 0.001
Offering price per share		$ 4.25
Gross proceeds from sale of common stock shares		$ 43,100,000
Secondary Offering [Member] \| 2016 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Offering price per share	$ 2.75
Gross proceeds from sale of common stock shares	$ 25,700,000
Over Allotment Option [Member] \| 2015 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock		9,425,000
Sale of stock price per share net of fees		$ 3.995
Over Allotment Option [Member] \| 2016 Underwriting Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock	10,065,000
Sale of stock price per share net of fees	$ 2.585
At-The-Market Facility [Member]
Class Of Stock [Line Items]
Issuance of common stock			11,631,803
Gross proceeds from sale of common stock shares			$ 13,200,000
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Issuance of common stock from stock options exercises, net, Shares			11,631,803
Issuance of common stock			11,631,803
Gross proceeds from sale of common stock shares			$ 13,200,000
Common stock value reserved for future issuance				$ 36,400,000
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance				$ 86,400,000				$ 50,000,000
Equity Incentive Plan 2008 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued															1,521,584
Termination date of equity incentive plan			Jul. 01, 2018
Shares issued during the year			896,256
Equity Incentive Plan 2012 [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued							11,000,000			6,000,000		5,000,000		6,553,986
Shares available for issuance			13,464,720				28,553,986
Termination period of Equity Incentive Plan			10 years
Inducement Award Agreements [Member]
Class Of Stock [Line Items]
Common shares authorized to be issued						1,135,408			2,297,034

Stockholders' Equity - Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) - Restricted stock units (RSUs) [Member] - shares	12 Months Ended
	Mar. 31, 2019	Aug. 14, 2018	Mar. 31, 2018
Class Of Stock [Line Items]
Restricted stock awards granted	1,916,802
Number of shares allocated	2,080,723		2,035,345
CMO [Member]
Class Of Stock [Line Items]
Number of shares allocated		160,714

Stockholders' Equity - Summary of Company's Restricted Stock Unit Activity and Performance Based Restricted Stock Unit Activity (Detail) - $ / shares	4 Months Ended	8 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 12, 2018	Mar. 31, 2019
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares		2,035,345	2,035,345
Granted, Number of Shares			1,916,802
Vested, Number of Shares			(766,187)
Canceled / forfeited, Number of Shares			(1,105,237)
Ending balance, Unvested, Number of Shares	2,080,723		2,080,723
Beginning balance, Unvested, Weighted Average Price		$ 2.89	$ 2.89
Granted, Weighted Average Price			1.18
Vested, Weighted Average Price			2.39
Canceled / forfeited, Weighted Average Price			2.33
Ending balance, Unvested, Weighted Average Price	$ 1.80		$ 1.80
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares	158,706	200,470	200,470
Impact of modification, Number of Shares	0
Granted, Number of Shares	0	0
Vested, Number of Shares	0	(41,764)
Canceled / forfeited, Number of Shares	0	0
Ending balance, Unvested, Number of Shares	158,706	158,706	158,706
Beginning balance, Unvested, Weighted Average Price	$ 1.88	$ 1.88	$ 1.88
Impact of modification, Weighted Average Price	(0.74)
Granted, Weighted Average Price	0	0
Vested, Weighted Average Price	0	1.88
Canceled / forfeited, Weighted Average Price	0	0
Ending balance, Unvested, Weighted Average Price	$ 1.04	$ 1.88	$ 1.04

Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail) - Inducement Award Performance-Based Restricted Stock Units [Member]		12 Months Ended
	Aug. 23, 2017 USD ($) Tranche shares	Mar. 31, 2019 Tranche shares	Apr. 24, 2017 shares
Class Of Stock [Line Items]
Number of tranches \| Tranche	5
Award vesting percentage		100.00%
Number of tranches vested \| Tranche		0
Grant date fair values of tranches \| $	$ 165,000
Maximum [Member]
Class Of Stock [Line Items]
Number of shares allocated	208,822
Share-based Compensation Award, Tranche One [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2018
Share-based Compensation Award, Tranche One [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Share-based Compensation Award, Tranche One [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Share-based Compensation Award, Tranche Two [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2019
Share-based Compensation Award, Tranche Two [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Share-based Compensation Award, Tranche Two [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Share-based Compensation Award, Tranche Three [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2020
Share-based Compensation Award, Tranche Three [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Share-based Compensation Award, Tranche Three [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Share Based Compensation Award Tranche Four [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2021
Share Based Compensation Award Tranche Four [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Share Based Compensation Award Tranche Four [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
Share Based Compensation Award Tranche Five [Member]
Class Of Stock [Line Items]
Award vesting percentage	20.00%
Stock units vesting year	2020
Share based compensation arrangement, number of shares vested		41,764
Share based compensation arrangement, number of shares forfeited		8,352
Share based compensation arrangement, number of shares eligible to vest upon future performance		158,706
Share based compensation arrangement amendment description and terms		Based on the amendment to the vesting criteria, the remaining 158,706 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.
Share Based Compensation Award Tranche Five [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage	0.00%
Share Based Compensation Award Tranche Five [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage	120.00%
CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated			208,822

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail) - USD ($)			12 Months Ended
	Aug. 14, 2018	Apr. 24, 2017	Mar. 31, 2019	Mar. 31, 2018
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares			622,192	500,000
Weighted-average remaining contractual term of stock options exercisable			6 years 10 months 24 days
Weighted-average remaining contractual term of stock options outstanding			6 years 10 months 24 days
Number of common stock shares approved under ESPP			29,077,131
Expected life of options			6 years	6 years
2012 Plan [Member]
Class Of Stock [Line Items]
Issuances of common stock from stock option exercises, Shares			7,049,500
Inducement Award Agreement [Member]
Class Of Stock [Line Items]
Period for vesting schedule over start date		4 years
Award vesting conditions			These stock options vest over a four-year period, with a quarter of the option shares vesting on the one-year anniversary of the vesting commencement date and the remaining options shares vesting in equal quarterly installments over the next 12 quarterly periods.
Award vesting percentage			25.00%
Inducement Award Agreement [Member] \| CEO [Member]
Class Of Stock [Line Items]
Stock options granted		2,088,212
Inducement Award Agreement [Member] \| CMO [Member]
Class Of Stock [Line Items]
Stock options granted	974,694
2016 Employee Stock Purchase Plan [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP			1,500,000
Employee subscription rate			15.00%
Compensation amount per employee			$ 25,000
Number of shares per employee			10,000
Fair market value at discount			85.00%
Purchase period			6 months
Initial offering period			2016-09
Description of plan			Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Expected life of options			6 months	6 months
Shares issued under ESPP			96,385
Shares remaining available for purchase under ESPP			1,188,718

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance	10,132,312
Granted, Options Outstanding	8,024,194
Canceled, Options Outstanding	(5,495,050)
Exercised, Options Outstanding	(622,192)	(500,000)
Options Outstanding, Ending balance	12,039,264	10,132,312
Vested and Exercisable, Options Outstanding	3,810,831
Weighted-Average Exercise Price, Options Beginning balance	$ 4.01
Options granted, Weighted-Average Exercise Price	1.29
Options canceled, Weighted-Average Exercise Price	4.37
Options exercised, Weighted-Average Exercise Price	0.08
Weighted-Average Exercise Price, Options Ending balance	2.24	$ 4.01
Vested and Exercisable, Weighted-Average Exercise Price	$ 3.68
Aggregate Intrinsic Value, Options Beginning balance	$ 591,082
Options Exercised, Aggregate Intrinsic Value	561,591
Aggregate Intrinsic Value, Options Ending balance	0	$ 591,082
Vested and Exercisable, Aggregate Intrinsic Value	$ 0

Stockholders' Equity - Warrants - Additional Information (Detail) - USD ($)		1 Months Ended		12 Months Ended			36 Months Ended
	Dec. 31, 2014	Nov. 30, 2014	Sep. 30, 2014	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2016	Dec. 31, 2014
Class Of Stock [Line Items]
Warrants to purchase common stock	650,000	145,000	50,000	0			650,000
Warrants maturity term		5 years	5 years
Warrants earned, service period		17 months
Number of warrant shares vested upon satisfaction of specific performance metrics					95,000
Volatility		73.40%		72.99%	76.86%
Risk-free interest rate		1.21%		2.75%	1.81%
Weighted-average remaining contractual term of options exercisable				6 years 10 months 24 days
Consultation Service Agreement September 2014
Class Of Stock [Line Items]
Recognized expenses of warrants	$ 237,000
Consultation Service Agreement November 2014
Class Of Stock [Line Items]
Recognized expenses of warrants						$ 6,000
Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share				$ 6.84
Warrants maturity term							2 years
Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share				$ 7.62
Warrants maturity term							5 years
Warrants [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share		$ 6.84	$ 7.62
Estimated fair value of warrants		$ 74,000
Weighted-average remaining contractual term of options exercisable				6 months 10 days
Warrants [Member] \| Consultants [Member]
Class Of Stock [Line Items]
Number of warrants exercised				0	0
Warrants [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 1.70						$ 1.70
Warrants [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Warrants exercisable price, per share	$ 3.24						$ 3.24

Stockholders' Equity - Summary of Warrant Activity (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance	10,132,312
Granted, Options Outstanding	8,024,194
Expired / Canceled, Options Outstanding	(5,495,050)
Exercised, Options Outstanding	(622,192)	(500,000)
Options Outstanding, Ending balance	12,039,264	10,132,312
Weighted-Average Exercise Price, Options Beginning balance	$ 4.01
Granted, Weighted-Average Exercise Price	1.29
Expired / Canceled, Weighted-Average Exercise Price	4.37
Exercised, Weighted-Average Exercise Price	0.08
Weighted-Average Exercise Price, Options Ending balance	$ 2.24	$ 4.01
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Outstanding, Beginning balance	220,000
Granted, Options Outstanding	0
Expired / Canceled, Options Outstanding	(75,000)
Exercised, Options Outstanding	0
Options Outstanding, Ending balance	145,000	220,000
Weighted-Average Exercise Price, Options Beginning balance	$ 7.19
Granted, Weighted-Average Exercise Price	0
Expired / Canceled, Weighted-Average Exercise Price	7.36
Exercised, Weighted-Average Exercise Price	0
Weighted-Average Exercise Price, Options Ending balance	$ 7.11	$ 7.19

Stockholders' Equity - Common Stock Reserved for Future Issuance (Detail)	Mar. 31, 2019 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	29,077,131
Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	13,464,720
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,500,000
Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	145,000
Stock options [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	8,976,358
Stock options [Member] \| 2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,188,718
Stock options [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	3,062,906
Restricted stock units (RSUs) [Member] \| Equity Incentive Plan 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,920,009
Restricted stock units (RSUs) [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	160,714
Performance-Based Restricted Stock Units [Member] \| Inducement Award Agreement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	158,706

Commitments and Contingencies - Additional Information (Detail)		12 Months Ended		36 Months Ended	81 Months Ended
	Nov. 30, 2018 USD ($)	Mar. 31, 2019 USD ($) ft²	Mar. 31, 2018 USD ($)	Jan. 31, 2018 USD ($) ft²	Mar. 31, 2019 USD ($)
Commitments And Contingencies [Line Items]
Rent expense per month		$ 120,000
Base rent escalators		3.00%		3.00%	3.00%
Office space under lease agreement \| ft²		45,580
Landlord tenant improvements funded amount	$ 500,000
Area of leased office space \| ft²				5,803
Lease term				36 months
Lease rental period start date				Feb. 01, 2015
Lease rental period end date				Jan. 31, 2018
Base rent under the lease				$ 12,000
Leasehold improvements					$ 518,000
Rent expense		$ 1,173,000	$ 1,458,000
Lease Term For Remainder of Total Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Lease expiration date		Aug. 31, 2024
Lease option termination description		option to terminate the lease on or after September 1, 2019 with 9 months prior written notice.
Lease Term For 14,685 of Total Rentable Square Footage [Member]
Commitments And Contingencies [Line Items]
Office space under lease agreement \| ft²		14,685
Lease expiration date		Oct. 31, 2018
Lease Amendment
Commitments And Contingencies [Line Items]
Lease expiration date		Aug. 31, 2024
Lease Amendment \| Maximum [Member]
Commitments And Contingencies [Line Items]
Tenant improvements		$ 500,000			$ 500,000

Commitments and Contingencies - Future Minimum Annual Operating Lease Payments (Detail) $ in Thousands	Mar. 31, 2019 USD ($)
Commitments And Contingencies Disclosure [Abstract]
Fiscal year ended March 31, 2020	$ 1,084
Fiscal year ended March 31, 2021	1,116
Fiscal year ended March 31, 2022	1,158
Fiscal year ended March 31, 2023	1,183
Fiscal year ended March 31, 2024	1,218
Thereafter	514
Total	$ 6,273

Licensing Agreements and Research Contracts - Additional Information (Detail) - USD ($)	1 Months Ended					12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	May 31, 2011	Mar. 31, 2010	Mar. 31, 2009	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense of licenses						$ 14,000	$ 13,600
Weighted average remaining amortization period for all licenses						11 years
Annual amortization expense of licenses year 1						$ 14,000
Annual amortization expense of licenses year 2						14,000
Annual amortization expense of licenses year 3						14,000
Annual amortization expense of licenses year 4						14,000
Annual amortization expense of licenses year 5						14,000
University of Missouri [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty fees percentage minimum				1.00%	1.00%
Royalty fees percentage maximum				3.00%	3.00%
Minimum annual royalty paid	$ 25,000	$ 25,000
Excess of minimum annual royalties payment						0	0
Expected expiration year of license agreement					2029
Upfront payment						$ 0	$ 0
Clemson University [Member]
Finite-Lived Intangible Assets [Line Items]
Minimum annual royalty payment due								$ 40,000	$ 20,000	$ 20,000
Clemson University [Member] \| Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Royalty fees percentage minimum			1.50%
Royalty fees percentage maximum			3.00%
Expected expiration year of license agreement			2024-05

Licensing Agreements and Research Contracts - Schedule of Capitalized License Fees (Detail) - Licensing Agreements [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Finite-Lived Intangible Assets [Line Items]
License fees	$ 218	$ 218
Less accumulated amortization	(81)	(67)
License fees, net	$ 137	$ 151

Income Taxes - Summary of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018
Deferred tax assets:
Net operating loss carry forwards	$ 0	$ 0
Research and development credits	0	0
Depreciation and amortization	28	25
Accrued expenses and reserves	886	1,050
Stock compensation	3,941	3,753
Other, net	20	8
Total deferred tax assets	4,875	4,836
Valuation allowance	(4,875)	(4,836)
Deferred tax assets net	$ 0	$ 0

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits	$ 0
Increase (decrease) in valuation allowance	39,000	$ (3,200,000)
Federal net operating loss carryforwards	170,300,000
State net operating loss carryforwards	$ 49,200,000
Federal net operating loss carryforwards (“NOLs”) expiring year	2028
State net operating loss carryforwards (“NOLs”) expiring year	2028
Federal research tax credit carryforwards expiration period	2028
Federal statutory tax rate	21.00%	35.00%
Valuation allowance for deferred tax	$ 2,700,000
Accrued expense regarding interest or penalties	0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	24,100,000
Research tax credit carryforwards	$ 4,000,000
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Percentage of future taxable income to be offset	80.00%
State [Member]
Operating Loss Carryforwards [Line Items]
Research tax credit carryforwards	$ 3,600,000

Related Parties - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 30, 2018	Sep. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Cirius Therapeutics, Inc., [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services			$ 281,000
Revenue recognized from related parties agreement			120,000	$ 161,000
Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Revenue recognized from related parties agreement				358,000
Viscient Biosciences [Member] \| Study Materials [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services		$ 2,000
Revenue recognized from related parties agreement			2,000
Viscient Biosciences [Member] \| Research Services [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services	$ 142,000
Revenue recognized from related parties agreement			42,000
Viscient Biosciences [Member] \| Samsara [Member] \| Primary Human Cell-based Products [Member]
Related Party Transaction [Line Items]
Amount of transactions with related party for providing services			165,000
Revenue recognized from related parties agreement			$ 96,000	$ 14,000

Recent Accounting Pronouncements - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2019	Mar. 31, 2018	Nov. 01, 2016
Change In Accounting Estimate [Line Items]
Restricted cash	$ 79	$ 127
Lessee, operating lease, renewal term	12 months
Operating lease, right-of-use asset	$ 4,500
Operating lease, liability	$ 5,000
Accounting Standards Update 2016-18 [Member]
Change In Accounting Estimate [Line Items]
Restricted cash			$ 100

Subsequent Events - Additional Information (Detail) - USD ($) $ in Thousands	2 Months Ended	12 Months Ended
	Jun. 06, 2019	Mar. 31, 2019	Mar. 31, 2018
Subsequent Event [Line Items]
Common stock, shares issued		124,015,429	111,032,957
Net proceeds from sale of common stock		$ 13,327	$ 9,381
At-The-Market Facility [Member]
Subsequent Event [Line Items]
Common stock, shares issued		11,631,803
Net proceeds from sale of common stock		$ 13,200
Subsequent Event [Member] \| At-The-Market Facility [Member]
Subsequent Event [Line Items]
Common stock, shares issued	6,087,382
Net proceeds from sale of common stock	$ 5,000

Defined Contribution Plan - Additional Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Defined Benefit Pension Plans And Defined Benefit Postretirement Plans Disclosure [Abstract]
Percentage of employees contribution	6.00%
Administration expenses	$ 240,000	$ 337,000

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Mar. 31, 2019 shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0